Phase III induction therapy with docetaxel and carboplatin in NSCLC IIIA/IIIIB: FDG-PET response predicts overall and disease-free survival. 2005 Proc ASCO Annual Meeting Proceedings - Griesinger, F; Pverbeck, T; Dorge, B (J Clin Oncol, 2005)
et al.